Research graph
References from The Efficacy of Immune-checkpoint Inhibitors in Combination with Definitive Chemoradiotherapy in Non-metastatic Esophageal SCC: A Systematic Review and Meta-analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Combination of immune checkpoint inhibitors and radiotherapy in locally advanced esophagogastric junction adenocarcinoma: A review
10.1002/cncr.35561 · 2024 · External reference
Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trial
10.1016/j.eclinm.2024.102471 · 2024 · External reference
How to perform a meta-analysis with R: a practical tutorial
2019 · External reference
Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma – a multicenter phase 2 trial (EPOC1802)
10.1038/s43018-025-00918-1 · 2025 · External reference
Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102
10.1200/jco.2005.04.7118 · 2007 · External reference
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 · External reference
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
10.1097/coc.0000000000000239 · 2016 · External reference
Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab
10.1038/s41467-024-46307-7 · 2024 · External reference
Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002)
10.1200/jco-25-03044 · 2026 · External reference
Neoadjuvant chemotherapy may not benefit esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy
10.1016/j.jcma.2017.06.014 · 2017 · External reference
Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy
10.1093/oncolo/oyad094 · 2023 · External reference
Mechanistic rationales for combining immunotherapy with radiotherapy
10.3389/fimmu.2023.1125905 · 2023 · External reference
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
10.1016/s1470-2045(14)70028-2 · 2014 · External reference
Patterns of recurrence following definitive chemoradiation for patients with proximal esophageal cancer
10.1016/j.ejso.2021.02.001 · 2021 · External reference
Induction immunochemotherapy followed by radiotherapy for patients with unresectable locally advanced or metastatic esophageal cancer: A propensity score-matched analysis
10.1016/j.intimp.2023.110955 · 2023 · External reference
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
10.1056/nejmoa2111380 · 2022 · External reference
Induction immunochemotherapy followed by concurrent chemoradiotherapy improves survival in unresectable esophageal cancer: a systematic review, meta-analysis, and network meta-analysis
2026 · External reference
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus
10.1056/nejm199206113262403 · 1992 · External reference
Immunotherapy combined with definitive chemoradiotherapy for locally advanced unresectable esophageal squamous cell carcinoma
10.3389/fimmu.2025.1646568 · 2025 · External reference
Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
2024 · External reference
Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro)
2022 · External reference
Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study)
10.1200/jco.20.03697 · 2021 · External reference
Long-Term Toxicity After Definitive Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus
10.1200/jco.2003.03.055 · 2003 · External reference
Current landscape of targeted therapy in esophageal squamous cell carcinoma
10.1016/j.currproblcancer.2024.101152 · 2024 · External reference
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
10.1016/s1470-2045(19)30626-6 · 2019 · External reference
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
10.1056/nejmoa2032125 · 2021 · External reference
Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study
10.1007/s00262-024-03649-x · 2024 · External reference
Efficacy of combined immunotherapy and predictive role of inflammatory markers in elderly ESCC patients
10.1080/20565623.2025.2564018 · 2025 · External reference
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy
10.1200/jco.2002.20.5.1167 · 2002 · External reference
Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus
10.1186/s13014-019-1270-8 · 2019 · External reference
Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trial
10.1016/j.eclinm.2025.103689 · 2026 · External reference
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.07.003 · 2022 · External reference
Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma (ImpactCRT): A single-arm, phase Ⅱ trial
2023 · External reference
Understanding the impact of radiation-induced lymphopenia: Preclinical and clinical research perspectives
2024 · External reference
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus
10.1200/jco.2005.00.034 · 2005 · External reference
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
10.1016/s0140-6736(21)01234-4 · 2021 · External reference
Clinical observation of anti-PD-1/PD-L1 immunotherapy plus concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
10.1016/j.cyto.2025.157096 · 2026 · External reference
ESMO–ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors
10.1016/j.annonc.2025.09.008 · 2026 · External reference
Combining radiotherapy with immunotherapy: the past, the present and the future
10.1259/bjr.20170157 · 2017 · External reference
The efficacy and safety of induction chemotherapy combined with sintilimab followed by concurrent chemoradiotherapy plus sintilimab sequencing maintaining with sintilimab for patients with unresectable locally advanced esophageal squamous cell carcinoma
10.1186/s12885-025-13457-w · 2025 · External reference
Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
10.1158/1078-0432.ccr-24-1236 · 2024 · External reference
Failure patterns in patients with esophageal cancer treated with definitive chemoradiation
10.1002/cncr.26586 · 2012 · External reference
Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma
10.1016/j.ebiom.2022.104371 · 2022 · External reference
Radiotherapy dose may not affect prognosis in ESCC patients receiving first-line chemoradiotherapy-immunotherapy: A multicenter retrospective study
10.1007/s00262-025-04261-3 · 2026 · External reference
Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety
10.1002/cncr.33424 · 2021 · External reference
Induction chemotherapy plus definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: Long-term results and exploratory analyses of a randomized controlled trial
10.1200/jco.2023.41.16_suppl.4061 · 2023 · External reference
Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinoma
2024 · External reference
Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study
10.1016/j.annonc.2026.07.413 · 2026 · External reference
A phase III multicenter randomized clinical trial of 60 Gy versus 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma
10.1158/1078-0432.ccr-21-3843 · 2022 · External reference
Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial
10.1001/jamasurg.2021.2373 · 2021 · External reference
Definitive chemoradiotherapy combined with anti-PD-1 immunotherapy for inoperable esophageal squamous cell carcinoma: a multicenter real-world study
10.1080/15384047.2025.2504726 · 2025 · External reference
A narrative review of combining radiation and immunotherapy in gastroesophageal cancers
10.21037/tcr-20-2210 · 2021 · External reference
High-dose versus standard-dose intensity-modulated radiotherapy with concurrent paclitaxel plus carboplatin for patients with thoracic esophageal squamous cell carcinoma: a randomized, multicenter, open-label, phase 3 superiority trial
10.1016/j.ijrobp.2022.11.006 · 2023 · External reference
Impact of consolidation immunotherapy after definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: a real-world multicenter study
10.1016/j.intimp.2025.115666 · 2025 · External reference
Radiotherapy: Brightness and darkness in the era of immunotherapy
10.1016/j.tranon.2022.101366 · 2022 · External reference
Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world
10.21037/atm-22-2779 · 2022 · External reference
Iparomlimab and tuvonralimab (QL1706) combined definitive chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (QL1706-IIT-02): a single arm, phase 2 trial
10.1016/j.eclinm.2026.103758 · 2026 · External reference
Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis
10.1038/s41467-021-25539-x · 2021 · External reference
Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial
10.1016/s1470-2045(23)00060-8 · 2023 · External reference
